Other Species / Isoforms
  CCNE2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S17-p
AKQQPQPsQtEsPQE
0 1
CCNE2 (human) AKQQPQPsQtEsPQE S17-p
CCNE2 (mouse) AKQHAQPNQPDsPQE N17
T19-p
QQPQPsQtEsPQEAQ
0 1
CCNE2 (human) QQPQPsQtEsPQEAQ T19-p
CCNE2 (mouse) QHAQPNQPDsPQETQ P19
S21-p
PQPsQtEsPQEAQII
Upstream
0 24
Treatment
  • anti-CD3
  • ischemia
  • MG132_withdrawal
CCNE2 (human) PQPsQtEsPQEAQII S21-p
CCNE2 (mouse) AQPNQPDsPQETQII S21-p
K31-ub
EAQIIQAkKRKTTQD
0 1
CCNE2 (human) EAQIIQAkKRKTTQD K31-ub
CCNE2 (mouse) ETQIIQAKKRKTAQD K31
K49-ub
RREEVTKkHQYEIRN
0 1
CCNE2 (human) RREEVTKkHQYEIRN K49-ub
CCNE2 (mouse) RKEEITKKHQYEIRN K49
S67-p
PVLSGGIsPCIIIEt
0 6
CCNE2 (human) PVLSGGIsPCIIIEt S67-p
CCNE2 (mouse) PVLSGGIsPCIIIEt S67-p
T74-p
sPCIIIEtPHKEIGT
Downstream
1 5
Effects on Modified Protein
  • protein degradation
  • ubiquitination
CCNE2 (human) sPCIIIEtPHKEIGT T74-p
CCNE2 (mouse) sPCIIIEtPHKEIGT T74-p
S337
PFVNVVKSTsPVKLK
0 2
CCNE2 (human) PFVNVVKSTsPVKLK S337
CCNE2 (mouse) PFVSVVKsVsPVKLK S337-p
S339-p
VNVVKSTsPVKLKTF
0 2
CCNE2 (human) VNVVKSTsPVKLKTF S339-p
CCNE2 (mouse) VSVVKsVsPVKLKtF S339-p
T345
TsPVKLKTFKKIPME
0 1
CCNE2 (human) TsPVKLKTFKKIPME T345
CCNE2 (mouse) VsPVKLKtFKKIPME T345-p
S383-p
FRKGGQLsPVCNGGI
0 12
CCNE2 (human) FRKGGQLsPVCNGGI S383-p
CCNE2 (mouse) YRKGGQLsPVCNGGI S383-p
T392-p
VCNGGIMtPPKsTEK
Downstream
2 11
Effects on Modified Protein
  • protein degradation
  • ubiquitination
CCNE2 (human) VCNGGIMtPPKsTEK T392-p
CCNE2 (mouse) VCNGGIMtPPKSTEK T392-p
S396-p
GIMtPPKsTEKPPGK
Downstream
1 0
Effects on Modified Protein
  • protein degradation
  • ubiquitination
CCNE2 (human) GIMtPPKsTEKPPGK S396-p
CCNE2 (mouse) GIMtPPKSTEKPPGK S396